BOSTON and ATLANTA, Aug. 7, 2023
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT)
("Inhibikase" or "Company"), a clinical-stage pharmaceutical
company developing protein kinase inhibitor therapeutics to modify
the course of Parkinson's disease, Parkinson's-related disorders
and other diseases of the Abelson Tyrosine Kinases, today announced
that it will report financial results for the second quarter ended
June 30, 2023, on Monday, August 14, 2023, after the close of U.S.
markets. Following the announcement, the Company will host a
conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023, to provide a corporate
update and review the financial results.
The conference call can be accessed by dialing 1-833-816-1414
(United States) or 1-412-317-0506
(International) with the conference code 7774190. A live webcast
may be accessed using the link here, or by visiting the investors
section of the Company's website at www.inhibikase.com. After the
live webcast, the event will be archived on Inhibikase's website
for approximately 90 days after the call.
About Inhibikase
(www.inhibikase.com)
Inhibikase Therapeutics,
Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company
developing therapeutics for Parkinson's disease and related
disorders. Inhibikase's multi-therapeutic pipeline focuses on
neurodegeneration and its lead program IkT-148009, an Abelson
Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of
Parkinson's disease inside and outside the brain as well as other
diseases that arise from Ableson Tyrosine Kinases. Its
multi-therapeutic pipeline is pursuing Parkinson's-related
disorders of the brain and GI tract, orphan indications related to
Parkinson's disease such as Multiple System Atrophy, and drug
delivery technologies for kinase inhibitors such as IkT-001Pro, a
prodrug of the anticancer agent imatinib mesylate that the Company
believes will provide a better patient experience with fewer
on-dosing side-effects. The Company's RAMP™ medicinal chemistry
program has identified a number of follow-on compounds to
IkT-148009 to be potentially applied to other cognitive and motor
function diseases of the brain. Inhibikase is headquartered in
Atlanta, Georgia with offices in
Boston, Massachusetts.
Social Media Disclaimer
Investors and others should
note that the Company announces material financial information to
investors using its investor relations website, press releases, SEC
filings and public conference calls and webcasts. The Company
intends to also use
Twitter, Facebook, LinkedIn and YouTube as
a means of disclosing information about the Company, its services
and other matters and for complying with its disclosure obligations
under Regulation FD.
Contacts:
Company Contact:
Milton H.
Werner, Ph.D.
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex
Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-report-second-quarter-financial-results-on-august-14-2023-301893399.html
SOURCE Inhibikase Therapeutics, Inc.